Endo Health Solutions Inc (NASDAQ:ENDP) swung to profit in fiscal Q1 amid fewer write-downs and special items, in addition to a modest revenue boost as strong sales expansion in its generic segment offset drops in other units.
The company announced a profit of $15.3 million or 14 cent per share, contrasted against a loss of $87.3 million or 75 cents per share in previous year.
Adjusted earnings without asset write-downs, acquisition-related impacts and other costs were up at $1.09 from 87 cents. Quarterly revenue moved up 2.6 percent to $709.5 million.
Thomson Reuters analysts survey most recently anticipated EPS of $1.07 on $736 million of revenue.
At the current trading session, Endo Health Solutions Inc (NASDAQ:ENDP) shares lose -1.03% to $37.53 while The Stock traded within the range of $36.51 – $37.96. In the past year, the stock has traded within a range of $25.00 – $38.05. The current session’s volume of 524,823.00 shares is down from the average daily trading volume of 2.41 million shares.
Aruba Networks, Inc (NASDAQ:ARUN) shatter its fiscal Q3 guidance as the company reported it observed weak customer orders in April amid the sluggish economy.
The wireless-equipment maker presently projects 11 cents to 12 cents per share in adjusted earnings and revenue in the range of $144 million to $147 million.
The corporation intends to announce its quarterly results on May 16.
Aruba Networks, Inc. (NASDAQ:ARUN) shares are down -20.61% to $17.50 while the stock is traded within the range of $17.50 – $18.05 in the current trading session. In the last 12 months the shares have traded between $12.36 and $26.78. The current session’s volume of 9.73 million shares is high than their average daily trading volume of 1.97 million shares,
DO NOT TRADE ANY STOCK WITHOUT LEVEL 2 STOCK QUOTES! QuoteDaddy.com delivers it's user with the most in-depth Level 2 Quotation System available on the Planet! NO Downloads, NO Widgets, NO Plugins required! Stay on TOP of your trades with QuoteDaddy.com! CLICK HERE TO START YOUR FREE 30-DAY TRIAL